Occasional review

Matrix metalloproteases and lung disease

C M O'Connor, M X FitzGerald

Development, tissue remodelling, cell migration, inflammation, angiogenesis, and wound healing are just some of the physiological processes in which the matrix metalloproteases (MMPs), a family of highly homologous endopeptidases, play a crucial part.¹⁻⁴ Collectively the MMPs can cleave most, if not all, the protein constituents of the extracellular matrix including collagen, proteoglycan, laminin, fibronectin, and elastin. In so doing they facilitate cell movement, reorientation, and dispersal. The production and action of the MMPs are subject to strict control, ensuring limited proteolysis of the extracellular matrix during cell migration, tissue remodelling and repair.¹⁻⁶ Inadequate regulation of MMP production or action has, however, been implicated in a wide range of pathological processes including several lung diseases, rheumatoid arthritis, periodontal and renal diseases, osteoarthritis, fibrotic disorders, and tumour invasion.⁷⁻¹²

Recent studies elucidating (1) the sequence homologies between members of the MMP family,¹³ (2) factors involved in the regulation of MMP expression,^{14,15} and (3) mechanisms of MMP activation and inhibition^{16,17} have added considerably to our knowledge of the crucial control mechanisms which can tip the balance of MMP action from normal homeostasis to pathological process. In this review the salient features of the action and regulation of MMPs

which contribute to their role in normal and diseased states will be outlined and evidence for their participation in lung disease discussed.

The matrix metalloproteases (MMPs)

Nine members of the MMP family have been identified. All are produced and secreted in a latent, proenzyme form. They require Zn^{2+} and Ca^{2+} ions for activity and are inhibited by a group of specific inhibitors – the tissue inhibitors of metalloproteases (TIMPs). Initially characterised and classified on the basis of their different substrate specificities and molecular weights (table 1), individual MMPs have been given various names by different groups. The International Union of Biochemistry and Molecular Biology has recently recommended a standardised system of nomenclature which will be used in this review.¹⁸ Alternative names are cited in table 1. The cDNA predicted amino acid sequence of the MMPs reflects a high degree of homology between family members. Three functional domains are evident: a propeptide domain which codes for the peptide released upon activation of the proenzyme; a catalytic domain containing the Zn^{2+} binding site; and a C-terminal domain which exhibits some homology with hemopexin and vitronectin (fig

Table 1 Characteristics of the matrix metalloproteases (MMPs)

Enzyme	Molecular weight* (kDa)	ECM substrates	Other names†
Interstitial collagenase (EC 3.4.24.7)	55	Collagens I, II, III (III > I) VII, VII, X, gelatin, proteoglycan (PG)-core protein	MMP-1 Fibroblast-type collagenase
Neutrophil collagenase (EC 3.4.24.34)	75	Same as interstitial collagenase but I > III	MMP-8 PMN-type collagenase
Gelatinase A (EC 3.4.24.24)	72	Gelatins, collagens IV, V, VII, X, XII, fibronectin, elastin, PG-core protein	MMP-2 72 kDa gelatinase 72 kDa type IV collagenase
Gelatinase B (EC 3.4.24.35)	92	Gelatins, collagens IV and V, elastin, PG-core protein	MMP-9 92 kDa gelatinase 92 kDa type IV collagenase
Stromelysin-1 (EC 3.4.24.17)	57	PG-core protein, laminin, fibronectin, gelatins, elastin, collagens III, IV, V, IX, X, interstitial collagenase proenzyme	MMP-3 Transin Proteoglycanase Proteoglycanase activator
Stromelysin-2 (EC 3.4.24.22)	57	Same as stromelysin-1	MMP-10 Transin-2
Stromelysin-3	ND	ND	MMP-11
Matrilysin (EC 3.4.24.23)	28	PG-core protein, laminin, fibronectin, collagen IV, gelatin, interstitial collagenase proenzyme	MMP-7 PUMP-1 Uterine metalloproteinase
Macrophage metalloelastase	55	Elastin, fibronectin	(None)

ECM = extracellular matrix.

* Molecular weight of proenzyme form.

† MMP numbering according to Nagase *et al.*¹⁶

Department of
Medicine and
Therapeutics,
Woodview, University
College, Dublin
C M O'Connor

St Vincent's Hospital,
Elm Park, Dublin,
Republic of Ireland
M X FitzGerald

Reprint requests to:
Dr C M O'Connor.

Received 26 August 1993
Returned to authors
26 October 1993
Revised version received
9 December 1993
Accepted for publication
20 December 1993

Figure 1 Prototype of domain structure of matrix metalloproteases

1). The propeptide domain contains a highly conserved PRCG(V/N)PD sequence which is involved in maintaining the stability of the latent proenzyme.¹⁹ In the catalytic domain two conserved histidines are thought to act as Zn²⁺ ligands. Matrilysin, the smallest of the MMPs, is composed of the propeptide and catalytic domains only. Other family members contain a C-terminal domain which plays a part in determining the substrate specificity of the collagenases and stromelysins, and is also involved in the interaction of MMPs with the inhibitors TIMP-1 and TIMP-2.^{20,21} The two gelatinases contain an additional 175 residue insert in the catalytic region which is similar to the collagen binding region of fibronectin. The larger of these two enzymes, gelatinase B, contains a second insert at the C-terminal end of the catalytic domain which exhibits some homology to the α_2 chain of type V collagen. These inserted domains are involved in determining the substrate binding capabilities of the gelatinases.²²

DEGRADATION OF EXTRACELLULAR MATRIX COMPONENTS

Between them the MMPs are capable of digesting all the major components of the extracellular matrix and basement membrane (table 1). The two collagenases display a unique ability to cleave the native helix of fibrillar collagen types I, II, and III. They hydrolyse a single bond located one quarter length from the collagen C-terminus to yield one quarter and three quarter fragments of the original helical molecule.²³ At body temperature the released fragments spontaneously denature into randomly coiled gelatin peptides which are further degraded by a range of proteases, including other members of the MMP family. The two collagenases digest a similar range of collagen substrates (table 1) but at different rates. The neutrophil enzyme

preferentially degrades type I collagen whereas interstitial collagenase prefers a type III substrate.²⁴

The major *in vivo* role of the gelatinases was initially thought to be the digestion of gelatin peptides released from fibrillar collagens by the collagenases.²⁵ It has since been shown that gelatinases degrade other collagen types, including native type IV collagen, the major constituent of cellular basement membranes.²⁶ This has led to the suggestion that their major *in vivo* role may be the digestion of basement membranes during inflammatory cell migration and tumour invasion.²⁷

While the gelatinases can also degrade elastin and fibronectin, the MMPs with the broadest substrate range are the stromelysins. They digest fibronectin, laminin, elastin, proteoglycan core protein, and several collagen types.¹⁶ An additional feature of stromelysin-1 is its ability to potentiate the activation of latent interstitial collagenase, suggesting a synergistic interaction between these MMPs.²⁸

SOURCE OF MMPs

Interstitial collagenase is produced by a range of stromal cells including fibroblasts, endothelial cells, osteoblasts, keratinocytes, chondrocytes, and hepatocytes.¹ Cells of the monocyte/macrophage lineage also produce this enzyme. In contrast, neutrophil collagenase is found only in polymorphonuclear leucocytes where it is produced during maturation and stored in intracellular granules prior to release.²⁹

Gelatinase A and B also differ in their cellular distribution. Gelatinase B is the only form found in polymorphonuclear leucocytes and is also the major gelatinase produced by macrophages.^{30,31} By comparison, connective tissue cells preferentially produce gelatinase A, although transformed fibroblasts, cells of neoplastic origin and stromal cells surrounding tumours can produce both enzymes.^{12,32,35} It is suggested that fibroblasts may be induced to express gelatinase B by tumour derived factors.³⁴

Stromelysins-1 and 2 are produced by various connective tissue cells and by macrophages. Distribution of stromelysin-3 is less well characterised. Similarly, while expression of matrilysin has been observed in monocytes and cells of the involuting uterus,^{35,36} its distribution is, as yet, poorly defined.

Table 2 Cytokine and pharmacological regulation of MMP and TIMP expression in stromal cells^{1,8,10,38-44}

Enzyme/inhibitor	Upregulation	Repression
Interstitial collagenase	IL-1 β , TNF α , PDGF, EGF, bFGF, TGF β , NGF	TGF β , IFN γ , IL-4, glucocorticoids, retinoids
Gelatinase A	TGF β	IL-10, IL-4, IFN γ
Gelatinase B	TGF β	TGF β , IFN γ , glucocorticoids, retinoids
Stromelysin-1	IL-1 β , TNF α , PDGF, EGF, bFGF, TGF α , NGF	TGF β (TIMP-2)
TIMP*	IL-1 β , TNF α , PDGF, bFGF, IL-6, IL-10, TGF β (TIMP-1), glucocorticoids, retinoids	

IL=interleukin; TNF=tumour necrosis factor; PDGF=platelet derived growth factor; EGF=epidermal growth factor; bFGF=basic fibroblast growth factor; TGF=transforming growth factor; NGF=nerve growth factor; IFN=interferon.

* Most studies do not distinguish between TIMP-1 and TIMP-2. TGF β is reported to have differing effects on the expression of these inhibitors, causing upregulation of TIMP-1 and repression of TIMP-2.^{40,43}

REGULATION OF MMP PRODUCTION BY CYTOKINES

In stromal cells MMP production is regulated at transcriptional level by a range of cytokines which influence the production and stability of MMP mRNAs (table 2). Expression of interstitial collagenase and stromelysin-1 is coordinately upregulated by interleukin 1 (IL-1), tumour necrosis factor α (TNF α), platelet derived growth factor (PDGF), endothelial growth factor (EGF), basic fibroblast growth factor (bFGF), neural growth factor (NGF), and the phorbol ester tumour promoters.¹⁸

Table 3 Differential degranulation of neutrophils in response to various stimuli⁴⁵⁻⁵⁰

Stimulus for degranulation	Granule type		
	Primary (elastase)	Secondary (collagenase)	Tertiary (gelatinase B)
FMLP:			
< 10 ⁻⁹ mol/l	-	-	+
> 10 ⁻⁷ mol/l	-	+	+
Ca ²⁺ ionophore:			
< 0.1 µmol/l	-	-	+
> 0.5 µmol/l	-	+	+
> 5.0 µmol/l	+	+	+
Fluoride (20 µmol/l)	-	-	+
Interleukin-8 (0.3 units/ml)	-	+	+
TNFα (1.0 nmol/l)	-	+	+

FMLP = f-Met-Leu-Phe; TNF = tumour necrosis factor.

Many of these cytokines also enhance production of TIMP-1 (table 2). This co-expression of enzyme and inhibitor may be important in confining degradation of extracellular matrix to areas close to the protease producing cell. In polarised cells MMPs exhibit a directional preference for secretion – for example, endothelial cells secrete MMPs from their basal compartment and not into the apical lumen.³⁷ In cell migration it is suggested that enzyme and inhibitor may be generated at different sites to enhance directional movement of the cell.⁶ Most authors report the downregulation of interstitial collagenase and stromelysin-1 gene expression by transforming growth factor β (TGFβ), interferon γ (IFNγ) and IL-4. TGFβ also abrogates the effects of IL-1, TNFα, EGF, and bFGF on the expression of both these genes.³⁸ TIMP-1 expression is enhanced by TGFβ, as is the production of collagen, fibronectin, proteoglycans, and glycosaminoglycans.³⁹ Thus, the overall effects of TGFβ is to enhance interstitial matrix formation by increasing production of matrix components, decreasing production of interstitial collagenase and stromelysin-1, and increasing production of TIMP-1. The effect of TGFβ on basement membrane components may be somewhat different. Recent studies indicate that expression of the gelatinases by fibroblasts and keratinocytes is significantly increased by TGFβ.³⁹⁻⁴¹ Expression of TIMP-2, which is a more effective inhibitor of the gelatinases than TIMP-1, is also upregulated by TGFβ.^{42,43} These effects may be of significance in regulating cell detachment from basement membranes during wound healing and tumour invasion.

Pharmacological modulation of stromal cell MMP production is observed with retinoids and corticosteroids.^{8,44} Both decrease transcription of interstitial collagenase and stromelysin-1. The retinoids also enhance TIMP-1 production.⁴⁴ The effects of these agents on gelatinase expression is not, as yet, defined.

MMP RELEASE FROM NEUTROPHILS

Neutrophil MMPs are stored in intracellular granules and released upon stimulation. Control of neutrophil MMP production is therefore governed by factors which affect neutrophil activation rather than gene transcription. Available evidence indicates that neutrophil collagenase and gelatinase B are stored in separate granules – collagenase in the secondary (or specific) granules and the gelatinase B in the tertiary granules.⁴⁵⁻⁴⁷ Although the contents of both granules are released upon neutrophil stimulation by a range of chemotactic and activation factors (table 3), gelatinase B release is observed at stimulus concentrations lower than those required to promote release of secondary granule contents. Sequential MMP release along a chemotactic gradient is therefore proposed.⁴⁵⁻⁴⁹ Exocytosis of MMP-containing granules is observed during neutrophil adherence and exudation suggesting that these enzymes play a part in neutrophil migration and connective tissue remodelling in early inflammation and wound healing.⁵⁰

MMP ACTIVATION

Activation of latent MMPs is a stepwise process involving destabilisation of the coordinate bond between the active site Zn²⁺ and a free cysteine in the conserved PRCG(V/N)PD propeptide sequence. This destabilisation induces a conformational change which unmasks the active site, leading to autolytic cleavage of the N-terminal propeptide (fig 2).⁵¹ In vitro a range of disparate reagents, including organomercurials and detergents, activate MMPs by disrupting the cysteine–Zn²⁺ bond. Serine proteases activate MMPs by digesting part of the propeptide sequence which stabilises the cysteine–Zn²⁺ bond. In the case of interstitial collagenase, the enzyme produced following activation by these agents can be further activated by stromelysin-1.¹³ The identity of the in vivo activators of the MMPs is still uncertain. The serine protease, plasmin, has been implicated in the activation of stromelysin-1 and interstitial collagenase, suggesting a cascade mechanism involving plasminogen, plasminogen activator, and stromelysin-1 in the activation of interstitial collagenase.⁵² Unlike the other MMPs, gelatinase A is not activated by serine proteases.¹⁶ This enzyme is activated by binding to a membrane associated protein which is sensitive to metalloprotease inhibitors and is induced by phorbol esters and TGFβ.⁵³ Whether the membrane associated protein is itself a protease or acts by enhancing the autolytic activation of the gelatinase is not clear. Neutrophil collagenase and gelatinase can be activated by hypochlorous acid (HOCl), a pro-

Figure 2 Schematic representation of the proposed mechanism for activation of matrix metalloproteases

duct of the respiratory burst which oxidises the Zn^{2+} chelating cystine.⁵⁴ However, as activation of neutrophil MMPs can occur prior to, and independently of, the respiratory burst,⁴⁶ the in vivo relevance of this activation mechanism remains speculative.

MMP INHIBITION

The coordinated production of MMPs and their specific tissue inhibitors in a range of developing and remodelling situations suggest that TIMPs play a significant role in the regulation of MMP activation in vivo.⁵⁵ Four TIMPs have been reported and two – TIMP-1 and TIMP-2 – have been characterised. Both characterised TIMPs inhibit the active forms of all MMPs, binding in a non-covalent manner to form a 1:1 complex. Interestingly, the inhibitors can also bind to the latent form of both gelatinases – TIMP-1 binding to the gelatinase B proenzyme and TIMP-2 to latent gelatinase A.³ In this manner TIMPs may exert additional control on MMP action by inhibiting the auto-activation of the gelatinases.

The plasma protein α_2 -macroglobulin is an effective inhibitor of MMP action in vitro.⁵⁶ Given the large size of this protein, however, its role in inhibiting MMPs released by stromal cells is probably minor except at inflammatory sites where increased capillary permeability causes leakage of plasma proteins. In these instances inhibition of α_2 -macroglobulin may be important as TIMP activity is destroyed by the action of serine proteases released by infiltrating neutrophils.⁵⁷

Matrix metalloproteases and the lung

Maintenance of the extracellular matrix scaffold which supports the alveolar structure is essential for normal lung function and is achieved by a dynamic balance between synthesis and degradation of extracellular matrix components. In the healthy lung MMPs – which are produced by virtually all resident lung cells including fibroblasts, alveolar macrophages, epithelial and endothelial cells – are involved in normal extracellular matrix turnover and also participate in the wound healing response following injury.^{7,58} Given their role in normal lung homeostasis, it is not surprising that the MMPs are implicated in a range of pulmonary diseases characterised by alterations in alveolar structure, or abnormal wound healing responses, including emphysema, adult respiratory distress syndrome (ARDS), interstitial fibrosis, granulomatous disease, lung cancer, and pleural disease.^{59–65} In subsequent sections of this review evidence for the participation of MMPs in the pathogenesis of these diseases is outlined (with the exception of emphysema, which has been the subject of a recent review in *Thorax*).⁶⁶

MMPs AND ARDS

Neutrophil collagenase has been detected in bronchoalveolar lavage (BAL) fluid from

patients with ARDS.^{67,68} The enzyme is present in active form, indicating that it has been activated subsequent to release and has evaded in vivo inhibition by TIMPs and α_2 -macroglobulin. The destructive potential of this unopposed activity in the lung is considerable and may contribute to the tissue damage observed during the acute inflammatory stage of disease. To our knowledge, lung tissue or BAL fluid from patients with ARDS have not been assessed for the presence of gelatinase B, the second MMP stored in polymorphonuclear leucocytes. Indirect evidence would, however, suggest that this enzyme is likely to be released during the process of neutrophil adhesion and migration into the lung in ARDS. The tertiary granules which contain both gelatinase B and the adhesion molecule Mac-1 (CD11b/CD18) are rapidly transported to the cell surface following stimulation of neutrophils by chemotactic and activation factors.⁶⁹ In addition, IL-8, which appears to have a significant role in promoting neutrophil-mediated inflammation and injury in ARDS, stimulates release of gelatinase B from neutrophils.^{49,70} Release of this MMP could contribute to the breakdown of alveolar basement membrane observed in ARDS.⁷¹ Morphological studies indicate that preservation of basement membrane is vital for effective repair, as this provides tissue cells with migratory pathways that ensure the maintenance of the original alveolar architecture.⁷² Thus, the extent of basement membrane digestion by gelatinase B may be a significant factor in determining disease outcome in ARDS.

Evidence from wound healing systems indicate that regulated MMP expression and production by stromal cells is required for tissue remodelling⁷³ – a process which presumably takes place in the lungs of ARDS survivors. It is suggested that the excessive fibrosis observed in the lungs of non-survivors is a result of an unregulated repair process.⁷⁴ Whether the outcome is repair or fibrosis, MMPs produced by alveolar fibroblasts, macrophages, epithelial and endothelial cells are likely to have a significant role. To date, however, the participation of these MMPs in ARDS has received little attention. A recent study which demonstrates increased interstitial collagenase expression in the lungs of rats following hyperoxic injury (a model with similarities to ARDS) suggests that this may prove a fruitful area for future investigation.⁷⁵

MMPs AND INTERSTITIAL FIBROSIS

As indicated above, fibrosis – the common end stage of several interstitial lung diseases – is thought to reflect an aberrant wound healing response. The injury which triggers the response varies from neutrophil mediated tissue damage (cryptogenic fibrosing alveolitis) to granuloma formation in response to known (extrinsic allergic alveolitis) and unknown (sarcoidosis) antigens, direct tissue damage (asbestos, silica), and injury resulting from abnormal immune responses (collagen vascular diseases). Whatever the initial cause, a

common feature of all the above mentioned diseases is the development of a chronic inflammation which causes continual and repeated injury to the alveoli over a prolonged period. This chronic injury may, as suggested for acute injury in ARDS, destroy the extracellular matrix scaffold of the alveoli to such an extent that the structural template required for normal repair is destroyed. The continued low grade inflammation also ensures that cells within the injured alveoli are constantly exposed to inflammatory cytokines which modulate their expression of a range of cell products involved in fibrosis including extracellular matrix proteins, MMPs, and TIMP (table 2).

MMPs can participate in the fibrotic process at two stages: (1) at the injury stage by degrading basement membrane and extracellular matrix constituents; and (2) at the "attempted repair" stage where modulation of the production or action of MMPs may contribute to the abnormal tissue remodelling observed. (It must be remembered, however, that both injury and attempted repair are likely to occur side by side in the fibrotic lung.)

Collagenase activity has been detected in BAL fluids from patients with cryptogenic fibrosing alveolitis, rheumatoid interstitial lung disease, sarcoidosis, and asbestosis.⁶³⁻⁷⁹ In all these cases the collagenase present displays characteristics of the neutrophil derived enzyme. In both rheumatoid interstitial lung disease and sarcoidosis, collagenase levels in BAL fluid were higher in patients with established fibrosis than in those without evidence of fibrotic scarring.^{63-77,78} In some patients with sarcoidosis the presence of collagenase in BAL fluid preceded pulmonary deterioration.⁸⁰ These studies suggest that neutrophil collagenase may play a part in tissue injury in fibrosis.

Information on the participation of interstitial collagenase in fibrosis comes largely from studies carried out by Selmán and colleagues. These investigators observed increased levels of immunoreactive interstitial collagenase in BAL fluids from patients with extrinsic allergic alveolitis.⁸¹ No relation between MMP levels in BAL fluid and subsequent disease outcome was observed, however. In contrast, when collagenolytic activity of lung tissue from patients with extrinsic allergic alveolitis was assessed, patients with the highest levels of activity subsequently healed or improved whereas those with lower than normal values deteriorated.⁶² The same authors also observed lower than normal collagenolytic activity in fibrotic tissue samples from patients with cryptogenic fibrosing alveolitis.⁸² Although the identity of the MMPs contributing to the collagenolytic activity measured is not clear, the higher rates observed in control tissue would suggest the involvement of MMPs from stromal, rather than inflammatory, cells. These results suggest that a rise in stromal MMP production/action may enhance repair, whereas decreased MMP activity may contribute to abnormal repair and the accumulation of collagen at fibrotic sites.

A unifying hypothesis on the involvement of MMPs in fibrosis encompassing all the above observations would involve (1) collagenase (and probably gelatinase B) released from inflammatory polymorphonuclear leucocytes contributing to initial tissue injury, and (2) a decrease in interstitial collagenase expression by fibroblasts and/or other stromal cells contributing to subsequent aberrant repair and accumulation of collagen. In this regard, Selmán and colleagues have noted that lung fibroblast lines from patients with cryptogenic fibrosing alveolitis constitutively produce less interstitial collagenase than lines from normal lung.⁸³ We have also observed decreased collagenase production in a fibroblast line derived from BAL cells recovered from a patient with systemic lupus erythematosus (unpublished observations). In vitro studies indicate that several cytokines known to be present in inflammatory situations, including TGF β , IL-4 and IFN γ , are capable of reducing expression of interstitial collagenase by fibroblasts and monocytes/macrophages (table 2). As previously indicated, TGF β also increases collagen production and production of TIMP-1. Studies which indicate that TGF β promotes gelatinase expression in fibroblasts^{39,40} raise the intriguing possibility that, while "driving" fibroblasts to produce and deposit components of the interstitial matrix, this cytokine also enhances their capability to degrade basement membrane. Thus, under the influence of this cytokine the action of fibroblasts would ideally "fit" that required for producing fibrosis in situations where the extent of injury and/or continued inflammation prevented healing.

While most studies have concentrated on the role of interstitial and neutrophil collagenases in interstitial fibrosis, the potential involvement of other MMPs cannot be ignored. We have detected gelatinase B in BAL fluids from patients with cryptogenic fibrosing alveolitis, extrinsic allergic alveolitis and sarcoidosis (unpublished results), and the transient expression and activity of gelatinase A by alveolar macrophages from patients with sarcoidosis has been observed by Garbisa *et al.*⁸⁴ As these MMPs are particularly potent in degrading basement membrane collagen, their release or production in the lung may contribute to tissue injury in these diseases.

MMPs AND LUNG CANCER

Tumour invasion and metastasis involves degradation of tissue basement membrane and interstitial matrix. In recent years considerable attention has focused on the role of MMPs in these processes, as increased MMP activity has been shown to be associated with the metastatic potential of both cultured tumour cells and malignant tissue.^{12,27} In the lung, expression of both gelatinases, stromelysin-3 and interstitial collagenase has been observed in various primary and metastatic tumours including adenocarcinomas, squamous cell, and small cell carcinomas.^{64,85} Because of their role in basement membrane digestion, the expression and production of the two forms of gelatinase has

received particular attention. While initial immunohistochemical localisation of gelatinase A suggested its production by malignant cells, subsequent *in situ* hybridisation studies have revealed that stromal cells are the major source of this enzyme in many tumours, including lung carcinomas.^{85,86} Emonard *et al* have recently reported the presence of a binding site for gelatinase A on the surface of breast adenocarcinoma cells.⁸⁷ These observations suggest a parasitic type interaction between malignant and stromal cells with the malignant cell binding gelatinase produced by stromal cells, hence gaining the capacity to migrate through tissue basement membrane. *In situ* hybridisation experiments indicate that gelatinase B is produced by both tumour and stromal cells, particularly tumour associated macrophages.^{12,64} Decreased production of MMP inhibitors may also contribute to tumour metastatic potential.⁸⁸ Khokka *et al* have demonstrated that antisense RNA down modulation of TIMP transforms normal Swiss 3T3 fibroblasts into malignant cells capable of forming metastatic tumours.⁸⁹ This transformation is accompanied by an increase in MMP expression. The opposite effect was observed by DeClerck *et al*.⁹⁰ These investigators transfected malignant cells with TIMP-2 cDNA and noted a decreased capacity for invasion in the transfected cells. Direct inhibition of MMP activity by a synthetic peptide containing a modified "copy" of the MMP Zn-binding sequence has also been shown to inhibit tumour cell invasion.⁹¹ While still at an early stage, these studies suggest that therapies aimed at decreasing MMP expression by tumour and stromal cells and/or inhibiting MMP activity may be of value in limiting the metastatic spread of a range of tumours.

MMPs IN PLEURAL FLUID

A role for MMPs in maintaining the integrity of the pleural space has recently been suggested by Hurewitz and colleagues. These investigators noted high levels of both gelatinases in pleural effusions from patients with malignant and non-malignant inflammatory diseases.⁹² The enzyme activity observed was inhibited by tetracyclines.⁹³ The authors suggest that gelatinases in pleural fluid may serve to dissolve adhesions and accumulated connective tissue following pleural injury, and that the action of tetracyclines in pleurodesis may be attributable to their ability to inhibit these enzymes.

Future directions

Research in recent years has highlighted the involvement of common cytokines and growth factors in a range of seemingly diverse processes including cell migration, proliferation and transformation; destructive inflammatory disorders; resorptive processes; fibrosis and tumorigenesis. The involvement of common mediators suggests similarities in underlying cellular mechanisms. *In vivo*, all of these pro-

cesses require or are accompanied by change and reorganisation of the surrounding extracellular matrix. The most likely mechanism by which cytokines and growth factors exert their modulating effects on the extracellular matrix is via the induction or repression of MMPs and their inhibitors.² Thus, the potential application of therapies targeted at MMP regulation is considerable. As outlined in this review, recent advances in our understanding of these regulatory mechanisms now make it possible to design and examine such therapies.

- 1 Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, *et al*. Matrix metalloproteinases: a review. *Crit Rev Oral Biol Med* 1993;4:197-250.
- 2 Matrisian LM. The matrix-degrading metalloproteinases. *Bioessays* 1992;14:455-63.
- 3 Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. *Am J Respir Cell Mol Biol* 1992;7:120-5.
- 4 Emonard H, Grimaud J-A. Matrix metalloproteinases. A review. *Cell Mol Biol* 1990;36:131-53.
- 5 Matrisian LM, Hogan BL. Growth factor-regulated proteases and extracellular matrix remodelling during mammalian development. *Curr Top Dev Biol* 1990;24:219-69.
- 6 Alexander DM, Werb Z. Extracellular matrix degradation. In: Haly E, ed. *Cell biology of the extracellular matrix*. 2nd ed. New York, Plenum Press: 1991:255-302.
- 7 Davidson JM. Biochemistry and turnover of lung interstitium. *Eur Respir J* 1990;3:1048-68.
- 8 Brinckerhoff CE, Delany AM. Cytokines and growth factors in arthritic diseases: mechanisms of cell proliferation and matrix degradation in rheumatoid arthritis. In: Kimball ES, ed. *Cytokines and inflammation*. Boca Raton: CRC Press, 1991: 109-43.
- 9 Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. *J. Periodontol* 1993;5:474-84.
- 10 Davies M, Martin J, Thomas GJ, Lovett DH. Proteinases and glomerular matrix turnover. *Kidney Int* 1992;31:671-8.
- 11 Brinckerhoff CE. Regulation of metalloproteinase gene expression: implications for osteoarthritis. *Crit Rev Eukaryot Gene Expr* 1992;2:145-64.
- 12 Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. *Breast Cancer Res Treat* 1993;24:209-18.
- 13 Docherty AJP, Murphy G. The tissue metalloproteinase family and the inhibitor TIMP: a study using cDNAs and recombinant proteins. *Ann Rheum Dis* 1990;49:469-79.
- 14 Jonat C, Stein B, Ponta H, Herrlich P, Rahmsdorf HJ. Positive and negative regulation of collagenase gene expression. *Matrix* 1992;Suppl 1:145-55.
- 15 Matrisian LM, Ganser GL, Kerr, LD, Pelton RW, Wood LD. Negative regulation of gene expression by TGFβ. *Mol Reprod Dev* 1992;32:111-20.
- 16 Nagase H, Ogata Y, Suzuki K, Engchild JJ, Salvesen G. Substrate specificities and activation mechanisms of matrix metalloproteinases. *Biochem Soc Trans* 1991;19:715-8.
- 17 Murphy G. The regulation of connective tissue metalloproteinases by natural inhibitors. *Agents Actions* 1991;35(Suppl):69-76.
- 18 Enzyme Nomenclature 1991. *Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes*. New York: Academic Press, 1992.
- 19 Sanchez-Lopez R, Nicholson R, Gesnel MC, Matrisian LM, Breathnach R. Structure-function relationships in the collagenase family member transin. *J Biol Chem* 1988;263:11892-9.
- 20 Murphy G, Allan JA, Willenbrock F, Cockett MI, O'Connell JP, Docherty AJP. The role of the C-terminal domain in collagenase and stromelysin specificity. *J Biol Chem* 1992;267:9612-7.
- 21 Murphy G, Willenbrock F, Ward RV, Cockett MI, Eaton D, Docherty AJP. The C-terminal domain for 72 kDa gelatinase is not required for catalysis but it is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. *Biochem J* 1992;283:637-41.
- 22 Collier IE, Krasnov PA, Strongin YA, Birkedal-Hansen H, Goldberg GI. Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen binding domain from human 92 kDa type IV collagenase. *J Biol Chem* 1992;267: 6776-81.
- 23 Fields GB, van Wart HE, Birkedal-Hansen H. Sequence specificity of human skin fibroblast collagenase. Evidence for the role of collagen structure in determining the collagenase cleavage site. *J Biol Chem* 1987;262:6221-6.
- 24 Mallia SK, Mookhtiar KA, Gao Y, Brew K, Dioszegi M, Birkedal-Hansen H, *et al*. Characterization of 58-kilodalton human neutrophil collagenase: comparison with human fibroblast collagenase. *Biochemistry* 1990;289: 10628-34.
- 25 Harris ED, Krane SM. An endopeptidase from rheumatoid

- synovial tissue culture. *Biochem Biophys Acta* 1972; 258:566-76.
- 26 Murphy G, McAlpine CG, Poll CT, Reynolds JJ. Purification and characterization of a bone metalloproteinase that degrades gelatin and types IV and V collagen. *Biochem Biophys Acta* 1985;831:49-58.
 - 27 Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. *Nature* 1980;284:67-8.
 - 28 Murphy G, Cockett MI, Stephens PE, Smith PJ, Docherty AJP. Stromelysin is an activator of procollagenase. *Biochem J* 1987;248:265-8.
 - 29 Hasty KA, Pourmotabed TF, Goldberg GI, Thompson JP, Spinella DG, Stevens RM, et al. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. *J Biol Chem* 1990; 265:11421-4.
 - 30 Hibbs MS, Hasty KA, Seyer JM, Kang AH, Mainardi CM. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. *J Biol Chem* 1985;260:2493-500.
 - 31 Mainardi CI, Hibbs MS, Hasty KA, Seyer JM. Purification of a type IV collagen degrading metalloproteinase from rabbit alveolar macrophages. *Coll Relat Res* 1984;4:479-92.
 - 32 Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. S40-transformed human lung fibroblasts secrete a 92 kDa type IV collagenase which is identical to that secreted by normal human macrophages. *J Biol Chem* 1989;264:17213-21.
 - 33 Mackay AR, Hartzler JL, Pelina MD, Thorgeirsson UP. Studies on the ability of 65-kDa and 95-kDa tumor cell gelatinases to degrade type IV collagen. *J Biol Chem* 1990;265: 21929-34.
 - 34 Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR. Activity of type IV collagenases in benign and malignant breast disease. *Br J Cancer* 1993;67:1126-31.
 - 35 Busiek DF, Ross FP, McDonnell S, Murphy G, Matrisian LM, Welgus HG. Matrilysin (putative metalloprotease: PUMP) is expressed in developing human mononuclear phagocytes. *J Biol Chem* 1992;267:9087-92.
 - 36 Woessner JF, Taplin CJ. Purification and properties of a small latent matrix metalloproteinase of the rat uterus. *J Biol Chem* 1988;263:16918-25.
 - 37 Unemori EN, Bourhana KS, Werb Z. Vectorial secretion of extracellular matrix proteins, matrix-degrading proteinases and tissue inhibitor of metalloproteinases by endothelial cells. *J Biol Chem* 1990;265:445-51.
 - 38 Wilder RL, Lafyatis R, Roberts AB, Case JP, Kumkumian GK, Sano H, et al. Transforming growth factor in rheumatoid arthritis. *Ann NY Acad Sci* 1990;593:197-207.
 - 39 Overall CM, Wrana JL, Sodek J. Transforming growth factor-beta regulation of collagenase, 72 kDa-progelatinase, TIMP and PAI-expression in rat bone cell populations and human fibroblasts. *Connect Tissue Res* 1989; 20:289-94.
 - 40 Overall CM, Wrana JL, Sodek J. Induction of formative and resorptive cellular phenotypes in human gingival fibroblasts by TGF- β and concanavalin A: regulation of matrix metalloproteinases and TIMP. *J Periodont Res* 1991;26:279-82.
 - 41 Salo T, Lyons JG, Rahemtulla F, Berkedal-Hansen H, Larjava H. Transforming growth factor- β , up-regulates type IV collagenase expression in cultured human keratinocytes. *J Biol Chem* 1991;266:11436-41.
 - 42 Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72 and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. *J Biol Chem* 1991;266:13070-5.
 - 43 Stetler-Stevenson WG, Brown PD, Oinisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2) mRNA expression in tumour cell lines and human tumour tissue. *J Biol Chem* 1990;265:13933-8.
 - 44 Clark SD, Kobayashi DK, Welgus HG. Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. *J Clin Invest* 1987;80:1280-8.
 - 45 Hibbs MB, Hasty KA, Kang AH, Mainardi CL. Secretion of collagenolytic enzymes by human polymorphonuclear leukocytes. *Coll Relat Res* 1984;4:467-77.
 - 46 Petreque PR, Todd RF, Devall LJ, Boxer LA, Curnutte JT. Association between gelatinase release and increased plasma membrane expression of the Mo1 glycoprotein. *Blood* 1987;69:605-10.
 - 47 Falloon J, Gallin JI. Neutrophil granules in health and disease. *J Allergy Clin Immunol* 1986;77:653-62.
 - 48 Hanlon WA, Stolk J, Davies P, Humes JL, Mumford R, Bonney RJ. rTNF α facilitates human polymorphonuclear leukocyte adherence to fibrinogen matrices with mobilization of specific and tertiary but not azurophilic granule markers. *J Leukoc Biol* 1991;50:43-8.
 - 49 Masure S, Proost P, Van Damme J, Opendenakker G. Purification and identification of 91-kDa neutrophil gelatinase release by the activating peptide interleukin-8. *Eur J Biochem* 1991;198:391-8.
 - 50 Wright DG, Gallin JI. Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. *J Immunol* 1979;123:258-94.
 - 51 Van Wart HE, Berkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. *Proc Natl Acad Sci USA* 1990; 87:5578-82.
 - 52 Gavrilovic J, Murphy G. The role of plasminogen in cell-mediated collagen degradation. *Cell Biol Int Rep* 1989; 13:367-75.
 - 53 Ward RV, Atkinson SJ, Slocombe PM, Docherty AJP, Reynolds JJ, Murphy G. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. *Biochim Biophys Acta* 1991; 1079:242-6.
 - 54 Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. *Proc Natl Acad Sci USA* 1986;83:4322-6.
 - 55 Matrisian LM. Metalloproteinases and their inhibitors in matrix remodelling. *Trends Genet* 1990;6:121-5.
 - 56 Cawston TE, Mercer E. Preferential binding of collagenase to alpha 2-macroglobulin in the presence of the tissue inhibitor of metalloproteinases. *FEBS Lett* 1986;209:9-12.
 - 57 Okada Y, Watanabe S, Nakanashi I, Kishi J, Hayakawa T, Watorek W, et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. *FEBS Lett* 1988;229:157-60.
 - 58 Hammar H. Wound healing. *Int J Dermatol* 1993;32:6-15.
 - 59 D'Armiento J, Dahal SS, Okaday, Berg RA, Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. *Cell* 1992;91:955-61.
 - 60 Petty TL. Protease mechanisms in the pathogenesis of acute lung injury. *Ann NY Acad Sci* 1991;624:267-77.
 - 61 Gadek JE, Fells GA, Zimmerman RL, Crystal RG. Role of connective tissue proteases in the pathogenesis of chronic inflammatory lung disease. *Environ Health Perspect* 1984;55:297-406.
 - 62 Selman M, Montano M, Ramos C, Chapela R, Gonzalez G, Vadillo F. Lung collagen metabolism and the clinical course of hypersensitivity pneumonitis. *Chest* 1988; 2: 347-53.
 - 63 O'Connor C, Odlum C, Van Breda A, Power C, FitzGerald MX. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis. *Thorax* 1988; 43:393-400.
 - 64 Urbanski SJ, Edwards DR, Maitland A, Leco JK, Watson A, Kossakowska AE. Expression metalloproteinases and their inhibitors in primary pulmonary carcinomas. *Br J Cancer* 1992;66:1188-94.
 - 65 Hurewitz AN, Zucker S, Mancuso P, Wu CI, Dimassimo BA, Lysik RM, et al. Human pleural effusions are rich in matrix metalloproteinases. *Chest* 1992;102:1808-14.
 - 66 Tetley TD. Proteinase imbalance: its role in lung disease. *Thorax* 1993;48:560-5.
 - 67 Christner P, Fein A, Goldberg S, Lippmann M, Abrams W, Weinbaum G. Collagenase in the lower respiratory tract of patients with adult respiratory distress syndrome. *Am Rev Respir Dis* 1985;131:690-5.
 - 68 Weiland JE, Davis WB, Holter JF, Mohammed JR, Dorinsky PM, Gadek JE. Lung neutrophils in the adult respiratory distress syndrome: clinical and pathophysiologic significance. *Am Rev Respir Dis* 1986;133:218-25.
 - 69 Mollinedo F, Pulido R, Lacal PM, Sanchez-Madrid F. Mobilisation of gelatinase-rich granules as a regulatory mechanism of early functional responses in human neutrophils. *Scand J Immunol* 1991;34:33-43.
 - 70 Donnelly SC, Strieter RM, Kunkel SL, Watz A, Robertson CR, Carter DC, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. *Lancet* 1993;341:643-7.
 - 71 Raghu G, Striker LJ, Hudson LD, Striker GE. Extracellular matrix in normal and fibrotic human lungs. *Am Rev Respir Dis* 1985;131:281-9.
 - 72 Roman JR, McDonald JA. Cellular processes in lung repair. *Chest* 1991;100:245-8.
 - 73 Fini ME, Girard MT, Matsubara M. Collagenolytic/gelatinolytic enzymes in corneal wound healing. *Acta Ophthalmol* 1992;202(Suppl):26-33.
 - 74 Bitterman PB. Pathogenesis of fibrosis in acute lung injury. *Am J Med* 1992;92(Suppl 6A):39S-43S.
 - 75 Devaskar U, Govindrajana W, Taylor W, Heyman S, DeMello D. Hyperoxia induces the gene expression of interstitial collagenase (type I) and increases type I collagenolytic activity in newborn rat lungs. *Am Rev Respir Dis* 1993;147:A413.
 - 76 Gadek JE, Kelman JA, Fells G, Weinberger SE, Horwitz AL, Reynolds HY, et al. Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. *N Engl J Med* 1979;301:737-42.
 - 77 Weiland JE, Garcia JGN, Davis WB, Gadek JE. Neutrophil collagenase in rheumatoid interstitial lung disease. *J Appl Physiol* 1987;62:628-33.
 - 78 Gilligan DM, O'Connor CM, Ward K, Moloney D, Bresnahan B, FitzGerald MX. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. *Thorax* 1990;45:591-6.
 - 79 Gadek J, Hunninghake G, Schoenberger C, Fells G, Crystal G. Pulmonary asbestosis and idiopathic pulmonary fibrosis: pathogenic parallels. *Chest* 1981;80(Suppl):63S.
 - 80 Ward K, O'Connor CM, Odlum C, Power C, FitzGerald MX. Pulmonary disease progress in sarcoid patients with and without bronchoalveolar lavage collagenase. *Am Rev Respir Dis* 1990;100:636-41.
 - 81 Selman M, Pardo A, Barquin N, Sansores R, Ramirez R, Ramos C, et al. Collagenase and collagenase inhibitors in bronchoalveolar lavage fluids. *Chest* 1991;100:151-5.
 - 82 Selman M, Montano M, Ramos C, Chapela R. Concentration biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. *Thorax* 1986;41:355-9.
 - 83 Pardon A, Selman M, Ramirez R, Ramos C, Montano M, Stricklin G, et al. Production of collagenase and tissue

- inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lungs. *Chest* 1992; 203:1085-9.
- 84 Garbisa S, Ballin M, Daga-Gordini D, Fastelli G, Naturale M, Negro A, *et al.* Transient expression of type IV collagenolytic metalloproteinase by human mononuclear phagocytes. *J Biol Chem* 1986;261:2369-75.
 - 85 Soini Y, Paakko, Autio-Harmainen H. Genes of laminin B₁ chain, α_1 (IV) chain of type IV collagen and 72-kd type IV collagenase are mainly expressed by the stromal cells of lung carcinomas. *Am J Pathol* 1993;142:1622-30.
 - 86 Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K. Localisation of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridisation. *Cancer Res* 1992;52:1336-41.
 - 87 Edmonard HP, Remacle AG, Noel AC, Grimaud JA, Stetler-Stevenson WG, Foidart JM. Tumor cell surface-associated binding site for the Mr 72,000 type IV collagenase. *Cancer Res* 1992;52:5845-8.
 - 88 Ponton A, Coulombo B, Skup D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. *Cancer Res* 1991;51:2138-43.
 - 89 Khokha R, Waterhouse P, Lala P, Zimmer M, Denhardt DT. Increased proteinase expression during tumor progression of tissue inhibitor of metalloproteinases cell lines down-modulated for levels: a new transformation paradigm? *J Cancer Res Clin Oncol* 1991;117:333-8.
 - 90 DeClerck YA, Perez N, Shimada H, Boone TC, Langly KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. *Cancer Res* 1992;52:701-8.
 - 91 Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. *Cancer Res* 1992;52:23563-6.
 - 92 Hurewitz AN, Zucker S, Mancuso P, Wu CL, Dimassimo B, Lysik RM, *et al.* Human pleural effusions are rich in matrix metalloproteinases. *Chest* 1992;102:1808-14.
 - 93 Hurewitz AN, Wu CL, Mancuso P, Zucker S. Tetracycline and doxycycline inhibit pleural fluid metalloproteinases. *Chest* 1993;103:1113-7.